美国食品和药物管理局批准新辅助Opdivo®（nivolumab）和化疗的围手术期治疗，然后手术和辅助单剂Opdivo治疗可治愈的非小细胞肺癌癌症（NSCLC）

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

小野制药等信源发布 2024-10-07 12:01



可切换为仅中文







This material is intended to notify the press release issued on October 3 (local time) by Bristol Myers Squibb, our license partner for Opdivo. Please click https://www.bms.com/media/press-releases.html for the original press release.

本材料旨在通知Opdivo许可证合作伙伴Bristol-Myers Squibb于10月3日（当地时间）发布的新闻稿。请点击https://www.bms.com/media/press-releases.html原始新闻稿。